Chimeric Therapeutics has reported a significant milestone in its ongoing clinical trials, wherein a patient diagnosed with Acute Myelogenous Leukemia (AML) has exhibited a complete response following treatment in the CHM CORE-NK + Vactosertib Phase 1b trial. This achievement marks a cancer treatment innovation, highlighting immunotherapy progress and a significant cell therapy milestone. Chimeric Therapeutics, […]
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in the evolving landscape of multiple myeloma treatment. This significant study assesses the effectiveness of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) against the standard therapies, which include combinations of pomalidomide, bortezomib, and dexamethasone […]
Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading global science and technology company, has agreed to acquire Mirus Bio from Gamma Biosciences for $600 million in cash, marking a significant transaction in the biotechnology and advanced therapy bioprocessing sector. This acquisition is set to enhance Merck’s capabilities in the fast-growing cell and gene therapy market. Mirus […]
Japanese pharmaceutical giant Takeda Pharmaceutical has announced a proposal to acquire TiGenix, a Belgium-based cell therapy company, for €520 million. This acquisition is aimed at expanding Takeda’s late-stage gastroenterology portfolio and enhancing its presence in the American specialty care market. TiGenix, established in 2000, specializes in the development of novel treatments for serious medical conditions […]
